SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: fred hayes who wrote (377)3/10/2003 11:41:03 AM
From: scaram(o)uche   of 631
 
>> Any thoughts <<

Well, we don't want too much chat in the thread, and there are some Isotechnika freaks around who might want to comment on comments, but.... the results are so outstanding that we really should highlight them.

The target for ISA247 is not novel. It is, however, represented as having lower toxicity than rapamycin, cyclosporin, etc.

So...... first, they need to demonstrate conclusively that they do have a molecule with reduced toxicity. Second, for severe psoriasis, they need to convince FDA that a psoriasis indication is warranted and patients that it is wise to take a general immunosuppressant.

There's lotsa room in transplantation for a molecule with reduced toxicity. If the improvement is incremental, trials will need to be VERY large before Novartis starts to sweat.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News